Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.

Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.

Item
http://www.wikidata.org/entity/Q36018566
Virulence diversity among bacteremic Aeromonas isolates: ex vivo, animal, and clinical evidences.Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia.Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective.Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.Impact of borderline minimum inhibitory concentration on the outcome of invasive infections caused by Enterobacteriaceae treated with β-lactams: a systematic review and meta-analysis.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Carbapenem susceptibility breakpoints, clinical implications with the moving target.In vitro antimicrobial activity of five essential oils on multidrug resistant Gram-negative clinical isolates.Bloodstream infections caused by IMP-8-producing Enterobacteriaceae isolates: the need for clinical laboratory detection of metallo-β-lactamases?Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
P2860

Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.

Item
http://www.wikidata.org/entity/Q36018566
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Carbapenem therapy for bactere ...... s of ertapenem susceptibility.
@ast
Carbapenem therapy for bactere ...... s of ertapenem susceptibility.
@en
type
label
Carbapenem therapy for bactere ...... s of ertapenem susceptibility.
@ast
Carbapenem therapy for bactere ...... s of ertapenem susceptibility.
@en
prefLabel
Carbapenem therapy for bactere ...... s of ertapenem susceptibility.
@ast
Carbapenem therapy for bactere ...... s of ertapenem susceptibility.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Carbapenem therapy for bactere ...... s of ertapenem susceptibility.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932